Phytocannabinoids and MS

(−)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis

(−)-β-caryophyllene (BCP), a functional non-psychoactive CB2 receptor agonist [12,13,14], is found in, for example, plant-derived oleoresins, essential oils, solutes, distillates, extracts, fermentations, infusions, and leachates, from several plants [15,16,17,18,19,20,21,22,23,24,25]. Furthermore, BCP showed analgesic, anti-inflammatory, neuroprotective, anti-depressive, anxiolytic, and anti-nephrotoxicity effects [12,13,26,27,28,29,30,31]. In addition, several studies support the evidence that cannabimimetic drugs, mainly CB2 ligands, might have therapeutic potential in numerous pathologies, including demyelinating diseases [32,33,34,35]. Cannabinoids, including phytocannabinoids, have the ability to downregulate leucocytes proliferation, promote both T cells and macrophages apoptosis, and also diminish secretion of pro-inflammatory cytokines. This confers to cannabinoids potent inflammatory and immunomodulatory activity.

Share this post

Leave a Reply

Your email address will not be published.